Published Real-World Experience Demonstrates VasQ™ External Support Improves Outcomes When Adopted as the Standard of Care

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Dr. Robert Shahverdyan, Head of Vascular Access Center at Asklepios Klinik Barmbek of Hamburg, Germany, has recently published a retrospective analysis of his first 32 consecutive radiocephalic (forearm) VasQ procedures in the Journal of Vascular Access. The paper demonstrated that using VasQ as the standard of care for radiocephalic fistulas resulted in a significant improvement in his center’s primary fistula failure and longer-term secondary patency rates with less repeat interventions when compared to historical controls.

Radiocephalic fistulas are the preferred vascular access to facilitate dialysis treatment as compared to other modalities despite the reportedly high rates of primary failure and need for frequent interventions. Historically, the primary fistula failure rate for radiocephalic fistulas at Dr. Shahverdyan’s center before the use of VasQ was 29%, which compares well to the typically higher rates reported in the clinical literature for this type of fistula. That primary failure rate has dropped significantly to 6% since he began using VasQ as the standard of care for his radiocephalic patients. Additionally, his rate of repeat procedures required to make the fistulas usable dropped from 0.62 per pt-yr to 0.26 per pt-yr with VasQ. For context, typically reported rates for repeat procedure are between 1 to 2 interventions per pt-yr in Europe with rates in the U.S. reported >3 per pt-yr. His data aligns well with previously reported clinical studies for VasQ for upper arm fistulas and shows that the adoption of VasQ as the standard of care improved patient outcomes of an already high performing center.

Dr. Shahverdyan commented, “Hemodialysis patients are a particularly challenging patient population with historically poor outcomes related to vascular procedures. As surgeons, we must be skeptically optimistic about any new technology that promises better outcomes for our patients until we see it perform in a real-world setting. After careful review of my results over the last few years, I was excited to learn of the beneficial impact VasQ has had on my hemodialysis patient outcomes and am happy that I can offer them a better option with VasQ as my new standard of care for their vascular access.”

“The results from Dr. Shahverdyan’s practice is a significant step forward for Laminate to meet our goal of providing surgeons tools to create more usable fistulas,” said Laminate CEO Tammy Gilon. “We are excited to continue to partner with physicians like Dr. Shahverdyan as they work to create functioning fistulas for each of their patients.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.